Archived Press Releases
Lilly to Acquire Sigilon Therapeutics
INDIANAPOLIS and CAMBRIDGE, Mass., June 29, 2023 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases. Since 2018, Lilly and Sigilon have worked […] Read More
Jun 29, 2023 | PDF Version
Sigilon Announces Reverse Stock Split of Common Stock
CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilon’s Fifth Amended and Restated Certificate of Incorporation to effect the reverse stock split at Sigilon’s Annual Meeting of […] Read More
May 22, 2023 | PDF Version
Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
SIG-002, Sigilon’s lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023 Pipeline prioritization extends anticipated cash runway into 2025 CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through […] Read More
May 9, 2023 | PDF Version
Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare […] Read More
Apr 18, 2023 | PDF Version
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023 SIG-002 demonstrated efficacy and durability in in vivo mouse models for up to 17 weeks Extended anticipated cash runway into 2025 CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), […] Read More
Mar 14, 2023 | PDF Version
Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Identified important optimization features for its platform to mitigate PFO risks in current and future programs Advanced iPS cell differentiation protocol for the diabetes program in preparation for anticipated IND-enabling studies in 2023 Continued optimization of the MPS-1 program, with plans to initiate IND-enabling studies in the second half of 2023 CAMBRIDGE, Mass., Nov. 10, […] Read More
Nov 10, 2022 | PDF Version
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategy CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the […] Read More
Aug 4, 2022 | PDF Version
Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business Highlights
On track to announce results from preclinical studies of SIG-005 in second half of 2022 Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ […] Read More
May 12, 2022 | PDF Version
Sigilon Therapeutics to Present at the Needham Healthcare Conference
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Healthcare Conference. The presentation will […] Read More
Apr 7, 2022 | PDF Version
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
Announced strategic reprioritization, with plans to advance mucopolysaccharidosis type I (MPS-1) and diabetes as lead indications as well as continued platform optimization Strengthened leadership team with appointment of new Chief Technical Operations Officer and other key leadership changes Current cash position expected to fund operating plans into 2024 CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) […] Read More
Mar 14, 2022 | PDF Version
Sigilon Therapeutics to Present at the Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Barclays Global Healthcare Conference. The […] Read More
Mar 14, 2022 | PDF Version
Sigilon Therapeutics Appoints Sarah Yuan, Ph.D., as Chief Technical Operations Officer
CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Sarah Yuan, Ph.D., as Chief Technical Operations Officer, effective March 7th, 2022. Dr. Yuan brings more than 20 years […] Read More
Feb 22, 2022 | PDF Version
Sigilon Therapeutics to Present Preclinical Data at the 18th Annual WORLDSymposium™ on Lysosomal Diseases, MPS-1 and MPS-6
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that two abstracts – including an oral presentation on MPS-1 – have been accepted for presentation at the upcoming 18th Annual WORLDSymposium™, […] Read More
Jan 31, 2022 | PDF Version
Sigilon Therapeutics Announces Strategic Reprioritization
– Company plans to prioritize MPS-1 and diabetes with continued focus on platform optimization – – Workforce reduction of approximately 38% – – Anticipated cash runway extended into 2024 – CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases […] Read More
Dec 13, 2021 | PDF Version
Sigilon Therapeutics Announces Update on SIG-001 Phase 1/2 Study in Hemophilia A
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that fibrosed spheres were observed during a retrieval procedure in a patient in its Phase 1/2 study of SIG-001 in severe or moderately […] Read More
Nov 29, 2021 | PDF Version
Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001 in hemophilia A by year-end On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021 Company appoints May Orfali, M.D., M.B.A, as Chief Medical Officer CAMBRIDGE, Mass., Nov. 10, 2021 […] Read More
Nov 10, 2021 | PDF Version
Sigilon Therapeutics to Participate in the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the upcoming Jefferies London Healthcare Conference. […] Read More
Nov 9, 2021 | PDF Version
Sigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has accepted the Company’s Clinical Trial Application (CTA) for […] Read More
Sep 9, 2021 | PDF Version
Sigilon Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in two upcoming healthcare investor conferences. Presentation Details: Event: Morgan Stanley […] Read More
Sep 2, 2021 | PDF Version
Sigilon Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
CAMBRIDGE, Ma., Aug. 10, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the second quarter ended June 30, 2021 as well as certain other business highlights. “While we remain focused on patient […] Read More
Aug 10, 2021 | PDF Version
Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases
Company selected for oral presentation on mucopolysaccharidosis-1 (MPS-1), demonstrating potential of SIG-005 to provide sustained production of active human alpha-L-iduronidase in a preclinical model CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today […] Read More
Jul 23, 2021 | PDF Version
Sigilon Therapeutics Appoints Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development
CAMBRIDGE, Mass., July 19, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Ajay Rai, M.B.A., as Senior Vice President, Head of Business Development. Most recently, Mr. Rai served as Vice President, Corporate […] Read More
Jul 19, 2021 | PDF Version
Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A
CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported that the U.S. Food and Drug Administration (FDA) has notified the Company that its Phase 1/2 study of SIG-001 in patients with severe […] Read More
Jul 9, 2021 | PDF Version
Sigilon Therapeutics Appoints Brooke Story, M.B.A., to its Board of Directors
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Brooke Story to its Board of Directors. “I am delighted to welcome Brooke to our Board,” said Rogerio Vivaldi, M.D., […] Read More
Jun 16, 2021 | PDF Version
Sigilon Therapeutics Appoints Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Philip Ashton-Rickardt, Ph.D., as Chief Scientific Officer (CSO). Most recently, Dr. Ashton-Rickardt served as Senior Vice President for Immunology at […] Read More
Jun 14, 2021 | PDF Version
Sigilon Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in a fireside chat during the Jefferies Virtual Healthcare Conference. The […] Read More
May 27, 2021 | PDF Version
Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ended March 31, 2021 as well as certain other business highlights. “We are continuing to execute on […] Read More
May 10, 2021 | PDF Version
Sigilon Therapeutics to Present at the BofA Securities 2021 Healthcare Conference
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the BofA Securities 2021 Healthcare Conference. The […] Read More
May 6, 2021 | PDF Version
Sigilon Therapeutics Announces Presentations at the American Society of Gene and Cell Therapy 24th Annual Meeting
Presentations include initial results from preclinical studies of expanded pipeline programs in immune-mediated and metabolic diseases CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that four abstracts were selected for presentation […] Read More
Apr 27, 2021 | PDF Version
Sigilon Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 08, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the 20th Annual Needham Virtual Healthcare Conference. […] Read More
Apr 8, 2021 | PDF Version
Sigilon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full year ended December 31, 2020 as well as certain other business highlights. “2020 was a […] Read More
Mar 18, 2021 | PDF Version
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation to SIG-007 for the treatment of Fabry disease, a progressive, life-threatening […] Read More
Mar 5, 2021 | PDF Version
Sigilon Therapeutics to Present at Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Barclays Global Healthcare Conference. The presentation […] Read More
Mar 4, 2021 | PDF Version
Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™
Results demonstrate potential of Company’s therapies developed using its novel Shielded Living Therapeutics™ platform to treat broad range of chronic diseases CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported results from several ongoing […] Read More
Feb 8, 2021 | PDF Version
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the 39th Annual J.P. Morgan Healthcare […] Read More
Jan 13, 2021 | PDF Version
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today […] Read More
Dec 17, 2020 | PDF Version
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the closing of its upsized initial public offering of 8,050,000 shares of its common stock, including the exercise in full by the […] Read More
Dec 8, 2020 | PDF Version
Sigilon Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the pricing of its upsized initial public offering of 7,000,000 shares of its common stock at a public offering price of $18.00 per share. […] Read More
Dec 3, 2020 | PDF Version
Sigilon Therapeutics to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., August 7, 2020 – Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences. Presentation Details: Event: BTIG Virtual Biotechnology Conference Date: Monday, August 10, […] Read More
Aug 7, 2020 | PDF Version
Sigilon Therapeutics Appoints Kavita Patel, M.D., to its Board of Directors
CAMBRIDGE, Mass., June 16, 2020 – Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for patients with chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Kavita Patel, M.D., to its Board of Directors. Dr. Patel, a practicing physician, has been a leading voice in health policy development and patient-centered […] Read More
Jun 16, 2020 | PDF Version
Sigilon Therapeutics Announces $80.3 Million Series B Financing to Advance Shielded Living Therapeutics™ to the Clinic
– Proceeds will advance first-in-human clinical trial for hemophilia A in 2020 and progression and expansion of Sigilon’s pipeline – CAMBRIDGE, Mass., March 17, 2020 – Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for patients with chronic diseases through its Shielded Living Therapeutics platform, today announced that it has completed a $80.3 million […] Read More
Mar 17, 2020 | PDF Version
Sigilon Therapeutics to Present at the 40th Annual Cowen & Co. Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2020 – Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer Rogerio Vivaldi, M.D., will discuss the company’s novel approach to cell therapy and outline upcoming clinical development plans at the 40th Annual Cowen & Co. […] Read More
Feb 25, 2020 | PDF Version
Sigilon Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan 7, 2020 – Sigilon Therapeutics, Inc., a biotechnology company developing functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer Rogerio Vivaldi, M.D., will discuss the company’s novel approach to cell therapy and outline upcoming clinical development plans at the 38th Annual J.P. Morgan Healthcare […] Read More
Jan 7, 2020 | PDF Version
Sigilon Therapeutics to Present Preclinical Data Showing Six Months Durability for Cell Therapies in Rare Blood Disorders
Data to be presented next month at the American Society of Hematology Annual Meeting CAMBRIDGE, Mass. — Nov. 6, 2019 — Sigilon Therapeutics announced today that it will present data at the American Society of Hematology Annual Meeting demonstrating that its novel Shielded Living TherapeuticsTM platform for rare bleeding disorders remains viable in animal models for at […] Read More
Nov 6, 2019
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-001 for the Treatment of Hemophilia A
CAMBRIDGE, Mass., Aug. 27, 2019 – Sigilon Therapeutics today announced it has received Orphan Drug Designation for SIG-001, an investigational therapy for hemophilia A that leverages Sigilon’s Shielded Living Therapeutics™ platform to implant cells engineered to produce stable blood plasma levels of factor VIII, a crucial clotting protein. “We are very pleased to have received Orphan […] Read More
Aug 27, 2019
Sigilon Therapeutics Presents Data Demonstrating Feasibility of Shielded Living Therapeutics™ Platform for Hemophilia A at ISTH 2019 Congress
CAMBRIDGE, Mass. — July 9, 2019 — Sigilon Therapeutics today presented preclinical data demonstrating the feasibility of cellular therapies for bleeding disorders developed with the company’s Shielded Living Therapeutics™ platform, which was designed to deliver functional cures for chronic diseases. The data were shared in an oral presentation at the International Society on Thrombosis and Haemostasis […] Read More
Jul 9, 2019
Sigilon Therapeutics Augments Intellectual Property Portfolio with Recent U.S. Patents
CAMBRIDGE, Mass. — June 10, 2019 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using its Shielded Living Therapeutics™ platform, today announced the addition to its patent portfolio of U.S. Patent Nos. 10,285,949 and 10,292,936, which are entitled “Modified alginates for cell encapsulation and cell therapy.” The patents are exclusively licensed to Sigilon and were granted to the Massachusetts Institute […] Read More
Jun 10, 2019
Sigilon Therapeutics Hires Glenn Reicin, Veteran Banking and Finance Strategist, as CFO
Three Additional Key Hires Strengthen Leadership Team CAMBRIDGE, Mass. — June 3, 2019 — Sigilon Therapeutics today announced the hiring of veteran banking and finance strategist Glenn Reicin, MBA, as Chief Financial Officer. In a significant expansion of its leadership team, Sigilon has also hired a General Counsel and experts in product development and translational medicine. […] Read More
Jun 3, 2019
Sigilon Therapeutics Appoints Veteran Biotech Industry Leader John Cox to Board of Directors
CAMBRIDGE, Mass. — May 7, 2019 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics™, today announced the appointment of distinguished biopharma executive John Cox, MBA, to its Board of Directors. Mr. Cox has over 25 years of experience in biopharmaceuticals, most notably in his former role as Chief […] Read More
May 7, 2019
Sigilon Therapeutics Delivers Oral Presentation on SIG-001 for Hemophilia A at 2019 ASGCT Meeting
CAMBRIDGE, Mass. — May 1, 2019 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using its Shielded Living Therapeutics™ platform, today delivered an oral presentation featuring data on its hemophilia A program (SIG-001) at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Washington, D.C. The data presented will support […] Read More
May 1, 2019
Sigilon Therapeutics to Participate in Multiple Upcoming Scientific Conferences
CAMBRIDGE, Mass. — April 3, 2019 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics™, is pleased to participate in a number of upcoming conferences and symposia. Dr. Deya Corzo, Chief Medical Officer of Sigilon, is one of a select group of experts invited to attend the 2nd […] Read More
Apr 3, 2019
Sigilon Therapeutics to Present at Multiple Upcoming Investor and Health Care Conferences
CAMBRIDGE, Mass. — March 11, 2019 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics™, today announced that Chief Executive Officer Rogerio Vivaldi will present at a number of upcoming high-profile investor and health care conferences. At the 6th Annual Rare Disease Market Access and Orphan Commercialization Summit, […] Read More
Mar 11, 2019
Sigilon Therapeutics Expands Intellectual Property Portfolio with New Patent Issued
CAMBRIDGE, Mass. — January 30, 2019 — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living Therapeutics™, today announced the expansion of its patent portfolio with a newly granted U.S. patent (Patent No. US 10,172,791 B2) that further builds on the company’s strong intellectual property position. The patent, which was granted to the […] Read More
Jan 30, 2019
Sigilon Therapeutics and MIT Announce Research Collaboration to Advance Programmable Living Therapeutics for Serious Chronic Diseases
CAMBRIDGE, Mass. — January 7, 2019 — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living Therapeutics, and the Massachusetts Institute of Technology today announced a strategic research collaboration. The collaboration leverages cutting-edge synthetic biology approaches developed by professor Ron Weiss of the MIT Synthetic Biology Center, an internationally recognized leader in the […] Read More
Jan 7, 2019
Sigilon Therapeutics Announces Appointment of Four New Members of Senior Management Team
CAMBRIDGE, Mass. — Nov. 13, 2018 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics, today announced the appointment of four new members of its senior management team as the company prepares to advance its lead therapeutic candidate into clinical trials. Deya Corzo, M.D., FACMG, joins the company […] Read More
Nov 13, 2018
Sigilon Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
Cambridge, Mass. — Oct. 1, 2018 — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops shielded living therapeutics, today announced that two members of its executive leadership team will present at the 2018 Cell & Gene Meeting on the Mesa in La Jolla, California. Chief Executive Officer Rogerio Vivaldi will provide an overview of […] Read More
Oct 1, 2018
Sigilon Therapeutics Announces Leadership Transition and Appoints Rare Disease Pioneer Rogerio Vivaldi, M.D., as Chief Executive Officer
Cambridge, Mass. –Aug. 14 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutics, today announced that Rogerio Vivaldi, M.D., has joined the company as Chief Executive Officer. Dr. Vivaldi joins the Sigilon team from Bioverativ, a Sanofi company. Paul Wotton, Ph.D., who has stepped back from the role of CEO to […] Read More
Aug 14, 2018
Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
INDIANAPOLIS and CAMBRIDGE, Mass., April 4, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics today announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes. Sigilon is a privately-held biopharmaceutical company that is focused on discovering and developing “living therapeutics” with its Afibromer™ technology […] Read More
Apr 4, 2018
Sigilon Therapeutics to Present at Cowen & Company 38th Annual Health Care Conference
CAMBRIDGE, Mass., March 9, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conference. Presentation details are as follows: Cowen & Company 38th Annual Health Care Conference Presenter: Paul Wotton, Ph.D., Chief Executive Officer Date: Monday, March 12, […] Read More
Mar 14, 2018
Sigilon Therapeutics Receives Advanced Therapy Medicinal Product Designation for Afibromer™-Based Living Therapeutic Program
CAMBRIDGE, Mass., March 8, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that its Afibromer™ Living Therapeutic candidate SIG-003 has been granted an Advanced Therapy Medicinal Product (ATMP) designation by the Committee for Advanced Therapies of the European Medicines Agency. The recommendation, adopted by the […] Read More
Mar 14, 2018
Sigilon Therapeutics to Present at Upcoming Conferences
CAMBRIDGE, Mass., Feb. 8, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conferences. Presentation details are as follows: BIO CEO & Investor Conference 2018 Presenter: Paul Wotton, Ph.D., Chief Executive Officer Date: Monday, Feb. 12, 2018 Time: […] Read More
Feb 9, 2018
Elsevier welcomes six biotech and pharma starts-ups to The Hive
Elsevier welcomes six biotech and pharma start-ups to The Hive, supporting the most cutting-edge research in industry Start-ups working on a range of technologies and discoveries – from AI to immunotherapy – receive complimentary access to Elsevier’s information solutions to accelerate innovation Share this: New York, January 31, 2018 Elsevier, the global information analytics business […] Read More
Feb 1, 2018
Sigilon Therapeutics to Present at Upcoming January Conferences
CAMBRIDGE, Mass., Jan. 2, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in January. Presentation details are as follows: Biotech Showcase 2018 Presenter: Paul Wotton, Ph.D., Chief Executive Officer Date: Monday, Jan. 8, 2018 Time: 1:45 p.m. […] Read More
Jan 4, 2018
Sigilon Therapeutics Appoints David E. Moller, M.D., as Chief Scientific Officer
CAMBRIDGE, Mass., Jan. 4, 2018 /PRNewswire/ — Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged Living Therapeutics, today announced the appointment of David E. Moller, M.D., to the position of Chief Scientific Officer. Dr. Moller brings a long history of experience in drug discovery and development to the company, including a focus on […] Read More
Jan 4, 2018
Sigilon Therapeutics to Host Interactive Webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Dec. 4, 2017
Sigilon Therapeutics to Host Interactive Webinar “Beyond Gene Therapies: The Next Wave of Protein-Generating Therapeutics” on Dec. 4, 2017 Presentations by Robert Langer and Daniel Anderson Followed by Interactive Q&A Session Open to the Public Moderated by Journalist Luke Timmerman CAMBRIDGE, Mass., Nov. 30, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops […] Read More
Nov 30, 2017
Sigilon Therapeutics to Present at the 2017 Biotech and Money Inv€$tival Showcase Conference in London
CAMBRIDGE, Mass., Nov. 10, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present at the upcoming 2017 Biotech and Money Inv€$tival Showcase, organized in partnership with Jefferies LLC, and attend the Jefferies […] Read More
Nov 10, 2017
Sigilon Therapeutics Appoints Eric Shaff to Board of Directors
CAMBRIDGE, Mass., Nov. 1, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the appointment of Eric Shaff, Chief Financial Officer of Seres Therapeutics (NASDAQ:MCRB), to the Sigilon Therapeutics board of directors. Mr. Shaff brings a long history of industry experience to the company’s board. “Mr. Shaff’s […] Read More
Nov 1, 2017
Sigilon Therapeutics to Present at the 2017 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Sept. 29, 2017 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of Operations, will present an overview of the company’s development programs at the Cell & Gene Meeting on the Mesa to be held […] Read More
Sep 29, 2017